<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390490</url>
  </required_header>
  <id_info>
    <org_study_id>XH-20-007</org_study_id>
    <nct_id>NCT04390490</nct_id>
  </id_info>
  <brief_title>Effects of Integrated Treatment of Traditional Medicine and Western Medicine for Sepsis-induced Cardiac Injury</brief_title>
  <official_title>Effects of Integrated Treatment of Traditional Medicine and Western Medicine for Sepsis-induced Cardiac Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective randomized controlled clinical trial will evaluate the safety and
      effectiveness of Shenfu injection combined with Neiguan acupoint stimulation for
      sepsis-induced cardiac injury, and it is expected to provide a new combination of traditional
      Chinese and Western medicine treatment for sepsis-induced cardiac injury.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 days mortalities</measure>
    <time_frame>28 days</time_frame>
    <description>28 days mortalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>28 days</time_frame>
    <description>Length of ICU stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard sepsis bundle treatment plus 0.9%nsaline solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard bundle treatment combined with traditional Chinese medicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of Shenfu injection and Neiguan acupoint stimulation</intervention_name>
    <description>Shenfu injection is a traditional Chinese herbal extracts, which could improve the cardiac function in multiple disease. Neiguan is an important acupoint in cardiovascular acupuncture treatment. Integrated treatment of Shenfu injection and Neiguan acupoint stimulation, combined with standard sepsis bundle, is expected to reduce the mortality in sepsis-induced cardiac injury.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SOFA≥2 with organ dysfunction

          -  Age &gt; 18 years

          -  cTnI＞0.03 ng/ml with/or LVEF≤50%

        Exclusion Criteria:

          -  Patients who will undergo immediate PCI Pregnant

          -  Lactating women

          -  Patients with mental disorders

          -  Patients are using other experimental drugs; Refusal to provide informed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bin He, PhD</last_name>
    <phone>021-25077828</phone>
    <email>hebinicu@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ethics Committee of Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 9, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

